{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:33:54Z","timestamp":1740123234672,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s10549-020-05715-1","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T17:05:01Z","timestamp":1591117501000},"page":"259-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer"],"prefix":"10.1007","volume":"182","author":[{"given":"Daniel","family":"Reinhorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinat","family":"Yerushalmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assaf","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Desnoyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramy R.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9557-4634","authenticated-orcid":false,"given":"Hadar","family":"Goldvaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"5715_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341\u20131352. https:\/\/doi.org\/10.1016\/S0140-6736(15)61074-1","journal-title":"Lancet"},{"key":"5715_CR2","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S, Carlsson L, Oca\u00f1a A (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. JNCI J Natl Cancer Inst 103:1299\u20131309. https:\/\/doi.org\/10.1093\/jnci\/djr242","journal-title":"JNCI J Natl Cancer Inst"},{"key":"5715_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx141","author":"H Goldvaser","year":"2018","unstructured":"Goldvaser H, Barnes TA, Seruga B, Cescon DW, Oca\u00f1a A, Ribnikar D et al (2018) Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx141","journal-title":"J Natl Cancer Inst"},{"key":"5715_CR4","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Th\u00fcrlimann","year":"2005","unstructured":"Breast International Group (BIG) 1-98 Collaborative Group, Th\u00fcrlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747\u20132757. https:\/\/doi.org\/10.1056\/NEJMoa052258","journal-title":"N Engl J Med"},{"key":"5715_CR5","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/s0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JGM et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet (London, England) 359:2131\u20132139. https:\/\/doi.org\/10.1016\/s0140-6736(02)09088-8","journal-title":"Lancet (London, England)"},{"key":"5715_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ctrv.2018.08.009","volume":"70","author":"I Algorashi","year":"2018","unstructured":"Algorashi I, Goldvaser H, Ribnikar D, Cescon DW, Amir E (2018) Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. Cancer Treat Rev 70:138\u2013143. https:\/\/doi.org\/10.1016\/j.ctrv.2018.08.009","journal-title":"Cancer Treat Rev"},{"key":"5715_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","volume":"377","author":"CJ van de Velde","year":"2011","unstructured":"van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel J-M et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321\u2013331. https:\/\/doi.org\/10.1016\/S0140-6736(10)62312-4","journal-title":"Lancet"},{"key":"5715_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1761","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. https:\/\/doi.org\/10.1002\/sim.1761","journal-title":"Stat Med"},{"key":"5715_CR9","unstructured":"Higgins JPT, Deeks JJ (2011) Meta-analysis of rare events. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions (version 5.1.0). Version 5.1.0 [updated March 2011] The Cochrane Collaboration"},{"key":"5715_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6481","author":"TD Stanley","year":"2015","unstructured":"Stanley TD, Doucouliagos H (2015) Neither fixed nor random: weighted least squares meta-analysis. Stat Med. https:\/\/doi.org\/10.1002\/sim.6481","journal-title":"Stat Med"},{"key":"5715_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/0895-4356(90)90093-5","volume":"43","author":"B Burnand","year":"1990","unstructured":"Burnand B, Kernan WN, Feinstein AR (1990) Indexes and boundaries for quantitative significance; in statistical decisions. J Clin Epidemiol 43:1273\u20131284","journal-title":"J Clin Epidemiol"},{"key":"5715_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein RL, Lazar NA (2016) The ASA Statement on p -values: context, process, and purpose. Am Stat 70:129\u2013133. https:\/\/doi.org\/10.1080\/00031305.2016.1154108","journal-title":"Am Stat"},{"key":"5715_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","volume":"73","author":"RL Wasserstein","year":"2019","unstructured":"Wasserstein RL, Schirm AL, Lazar NA (2019) Moving to a world beyond \u201cp > 0.05\u201d. Am Stat 73:1\u201319. https:\/\/doi.org\/10.1080\/00031305.2019.1583913","journal-title":"Am Stat"},{"key":"5715_CR14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","volume":"12","author":"MM Regan","year":"2011","unstructured":"Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1\u201398 randomised clinical trial at 8\u00b71 years median follow-up. Lancet Oncol 12:1101\u20131108. https:\/\/doi.org\/10.1016\/S1470-2045(11)70270-4","journal-title":"Lancet Oncol"},{"key":"5715_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.18.00440","volume":"37","author":"T Ruhstaller","year":"2019","unstructured":"Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertsen B, de Azambuja E et al (2019) Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1\u201398 trial. J Clin Oncol 37:105\u2013114. https:\/\/doi.org\/10.1200\/JCO.18.00440","journal-title":"J Clin Oncol"},{"key":"5715_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092. https:\/\/doi.org\/10.1056\/NEJMoa040331","journal-title":"N Engl J Med"},{"key":"5715_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","volume":"369","author":"R Coombes","year":"2007","unstructured":"Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman R, Jones S et al (2007) Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559\u2013570. https:\/\/doi.org\/10.1016\/S0140-6736(07)60200-1","journal-title":"Lancet"},{"key":"5715_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2010.33.7899","volume":"30","author":"JM Bliss","year":"2012","unstructured":"Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE et al (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol 30:709\u2013717. https:\/\/doi.org\/10.1200\/JCO.2010.33.7899","journal-title":"J Clin Oncol"},{"key":"5715_CR19","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1200\/JCO.2016.70.5640","volume":"35","author":"JP Morden","year":"2017","unstructured":"Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L et al (2017) Long-term follow-up of the intergroup exemestane study. J Clin Oncol 35:2507\u20132514. https:\/\/doi.org\/10.1200\/JCO.2016.70.5640","journal-title":"J Clin Oncol"},{"key":"5715_CR20","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1200\/JCO.2005.04.120","volume":"23","author":"F Boccardo","year":"2005","unstructured":"Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138\u20135147. https:\/\/doi.org\/10.1200\/JCO.2005.04.120","journal-title":"J Clin Oncol"},{"key":"5715_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl941","author":"F Boccardo","year":"2006","unstructured":"Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdl941","journal-title":"Ann Oncol"},{"key":"5715_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.ejca.2012.12.025","volume":"49","author":"F Boccardo","year":"2013","unstructured":"Boccardo F, Guglielmini P, Bordonaro R, Fini A, Massidda B, Porpiglia M et al (2013) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial. Eur J Cancer 49:1546\u20131554. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.025","journal-title":"Eur J Cancer"},{"key":"5715_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0888-x","author":"T Aihara","year":"2010","unstructured":"Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S et al (2010) Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-010-0888-x","journal-title":"Breast Cancer Res Treat"},{"key":"5715_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10549-014-3155-8","volume":"148","author":"T Aihara","year":"2014","unstructured":"Aihara T, Yokota I, Hozumi Y, Aogi K, Iwata H, Tamura M et al (2014) Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. Breast Cancer Res Treat 148:337\u2013343. https:\/\/doi.org\/10.1007\/s10549-014-3155-8","journal-title":"Breast Cancer Res Treat"},{"key":"5715_CR25","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S1470-2045(17)30419-9","volume":"18","author":"MGM Derks","year":"2017","unstructured":"Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EMK, Liefers GJ et al (2017) Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:1211\u20131220. https:\/\/doi.org\/10.1016\/S1470-2045(17)30419-9","journal-title":"Lancet Oncol"},{"key":"5715_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","volume":"366","author":"R Jakesz","year":"2005","unstructured":"Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet (London, England) 366:455\u2013462. https:\/\/doi.org\/10.1016\/S0140-6736(05)67059-6","journal-title":"Lancet (London, England)"},{"key":"5715_CR27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1200\/JCO.2011.36.8993","volume":"30","author":"PC Dubsky","year":"2012","unstructured":"Dubsky PC, Jakesz R, Mlineritsch B, P\u00f6stlberger S, Samonigg H, Kwasny W et al (2012) Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 30:722\u2013728. https:\/\/doi.org\/10.1200\/JCO.2011.36.8993","journal-title":"J Clin Oncol"},{"key":"5715_CR28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135\u20131141. https:\/\/doi.org\/10.1016\/S1470-2045(10)70257-6","journal-title":"Lancet Oncol"},{"key":"5715_CR29","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"M Baum","year":"2003","unstructured":"Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 98:1802\u20131810. https:\/\/doi.org\/10.1002\/cncr.11745","journal-title":"Cancer"},{"key":"5715_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1470-2045(06)70767-7","volume":"7","author":"A Buzdar","year":"2006","unstructured":"Arimidex, Tamoxifen, Alone or in Combination Trialists\u2019 Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633\u2013643. https:\/\/doi.org\/10.1016\/S1470-2045(06)70767-7","journal-title":"Lancet Oncol"},{"key":"5715_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 365:60\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(04)17666-6","journal-title":"Lancet"},{"key":"5715_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"JF Forbes","year":"2008","unstructured":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(07)70385-6","journal-title":"Lancet Oncol"},{"key":"5715_CR33","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMoa0810818","volume":"361","author":"H Mouridsen","year":"2009","unstructured":"BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Th\u00fcrlimann B, Paridaens R et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766\u2013776. https:\/\/doi.org\/10.1056\/NEJMoa0810818","journal-title":"N Engl J Med"},{"key":"5715_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Th\u00fcrlimann B, Mouridsen H, Mauriac L, Forbes JF et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of Study BIG 1\u201398. J Clin Oncol 25:486\u2013492. https:\/\/doi.org\/10.1200\/JCO.2006.08.8617","journal-title":"J Clin Oncol"},{"key":"5715_CR35","unstructured":"Gradishar WJ, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, et al (2019) NCCN Guidelines Version 1.2019 Breast Cancer NCCN Guidelines Panel Disclosures Continue \u2020 Medical oncology \u00b6 Surgery\/Surgical oncology \u00a7 Radiation oncology\/Radiotherapy \u2260 Pathology \u2021 Hematology\/Hematology oncology \u0444 Diagnostic\/Interventional radiology \u00a5 Patient advocate \u00de Internal medicine \u0178 Reconstructive surgery *Discussion Section Writing Committee"},{"key":"5715_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209\u2013219. https:\/\/doi.org\/10.1056\/NEJMoa1604700","journal-title":"N Engl J Med"},{"key":"5715_CR37","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/jnci\/djm246","volume":"99","author":"R Jakesz","year":"2007","unstructured":"Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E et al (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99:1845\u20131853. https:\/\/doi.org\/10.1093\/jnci\/djm246","journal-title":"J Natl Cancer Inst"},{"key":"5715_CR38","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/jnci\/djy218","volume":"111","author":"H Abdel-Qadir","year":"2019","unstructured":"Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV et al (2019) The risk of heart failure and other cardiovascular hospitalizations after early stage breast cancer: a matched cohort study. JNCI J Natl Cancer Inst 111:854\u2013862. https:\/\/doi.org\/10.1093\/jnci\/djy218","journal-title":"JNCI J Natl Cancer Inst"},{"key":"5715_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamacardio.2016.3841","volume":"2","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P et al (2017) A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol 2:88. https:\/\/doi.org\/10.1001\/jamacardio.2016.3841","journal-title":"JAMA Cardiol"},{"key":"5715_CR40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.5694\/j.1326-5377.2003.tb05621.x","volume":"179","author":"WS Liauw","year":"2003","unstructured":"Liauw WS, Day RO (2003) Adverse event reporting in clinical trials: room for improvement. Med J Aust 179:426","journal-title":"Med J Aust"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05715-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05715-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05715-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T05:08:40Z","timestamp":1622524120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05715-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["5715"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05715-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Yerushalmi reports personal fees from: Roche (Consulting, Invited speaker), Pfizer (Consulting), Novartis (Consulting), Teva (Invited speaker), Medison (Invited speaker), MSD (Invited speaker), Astra-Zeneca (Invited speaker) and Novartis (Invited speaker), all outside the submitted work. Dr. Moore reports <i>honorarium<\/i> fees from MSD and Roche, all outside the submitted work. Dr. Amir reports personal fees from Genentech\/Roche (Expert Testimony), personal fees from Apobiologix (Consulting), personal fees from Myriad Genetics (Consulting), personal fees from Agendia (Consulting), personal fees from Sandoz (Consulting), all outside the submitted work. Dr. Goldvaser reports personal fees from: Roche (honorarium), Pfizer (honorarium), Novartis (honorarium and consulting) all outside the submitted work. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}